Cas no 105816-04-4 (Nateglinide)

Nateglinide is a rapid-acting dipeptidyl peptidase-4 (DPP-4) inhibitor used in the treatment of type 2 diabetes mellitus. Its key advantages include: enhancing insulin secretion, facilitating glucose-dependent stimulation of insulin release, and providing rapid onset of action with short duration of effect, making it a valuable option for glycemic control management.

Nateglinide structure

Product Name:Nateglinide

CAS No:105816-04-4

MF:C₁₉H₂₇NO₃

MW:317.422585725784

MDL:MFCD00875706

CID:62573

PubChem ID:5311309

Update Time:2026-01-27

Nateglinide Chemical and Physical Properties

Names and Identifiers

- Nateglinide
- N-(trans-4-Isopropylcylcohexylcarbonyl)-D-phenylalanine
- N-[[TRANS-4-(1-METHYLETHYL)CYCLOHEXYL]CARBONYL]-D-PHENYLALANINE
- A4166
- A-4166
- ay4166
- DJN 608
- Fastic
- Fastic-d5
- Glinate
- N-[(trans-4-Isopropylcyclohexyl)carbonyl]-D-phenylalanine
- Natelide
- Senaglinide
- STARLIX
- Starlix DS
- Starsis
- 3-Phenyl-2-(4-propan-2-ylcyclohexyl)carbonylamino-propanoic acid
- Trazec
- Nateglinide [INN]
- AY 4166
- A 4166
- SDZ DJN 608
- 41X3PWK4O2
- (-)-N-(trans-4-Isopropylcyclohexanecarbonyl)-D-phenylalanine
- N-{[trans-4-(propan-2-yl)cyclohexyl]carbonyl}-D-phenylalanine
- (2R)-3-phenyl-2-[(4-propan-2-ylcyclohexanecarbonyl)amino]propanoic acid
- 105816-04-4
- 105746-37-0
- CHEBI:94617
- HY-B0422
- (2R)-2-[(4-isopropylcyclohexanecarbonyl)amino]-3-phenyl-propanoic acid
- 105816-06-6
- SW197528-2
- D-Phenylalanine, N-[[trans-4-(1-methylethyl)cyclohexyl]carbonyl]-
- nateglinida
- UNII-XTM4DQP5S5
- MFCD00875706
- Z1514053266
- EN300-27126236
- (2R)-2-[(4-isopropylcyclohexanecarbonyl)amino]-3-phenyl-propanoic acid;Nateglinide
- (r)-2-((1r,4r)-4-isopropylcyclohexanecarboxamido)-3-phenylpropanoic acid
- SCHEMBL22088
- Starsis (TN)
- ((1r,4R)-4-isopropylcyclohexane-1-carbonyl)-D-phenylalanine
- n-(trans-4-Isopropylcylolohexylcarboxyl)-d-phenylpropylicacid
- D-Phenylalanine, N-((4-(1-methylethyl)cyclohexyl)carbonyl)-, cis-
- SMR000466372
- UNII-41X3PWK4O2
- CCG-100898
- 2-[(4-Isopropyl-cyclohexanecarbonyl)-amino]-3-phenyl-propionic acid
- N-[[cis-4-(1-Methylethyl)cyclohexyl]carbonyl]-D-phenylalanine(Nateglinide Impurity)
- N-((cis-4-Isopropylcyclohexyl)carbonyl)-D-phenylalanine
- Tox21_111432
- AB00639979-06
- NATEGLINIDE [EP MONOGRAPH]
- GTPL6833
- Nateglinide, United States Pharmacopeia (USP) Reference Standard
- NATEGLINIDE [USP MONOGRAPH]
- SCHEMBL303827
- AB00639979-11
- HMS2051G20
- AB00639979-08
- AKOS005577723
- N-((cis-4-(1-Methylethyl)cyclohexyl)carbonyl)-D-phenylalanine
- AKOS015841612
- DJN-608
- NATEGLINIDE [ORANGE BOOK]
- N-[[4-(1-methylethyl)cyclohexyl]carbonyl]-D-phenylalanine
- NCGC00178741-03
- Nateglinide (Starlix)
- CHEMBL783
- (2R)-3-phenyl-2-{[4-(propan-2-yl)cyclohexyl]formamido}propanoic acid
- A801324
- Nateglinide cis Impurity
- Nateglinide impurity C
- SCHEMBL13753829
- D-phenylalanine, N-((trans-4-(1-methylethyl)cyclohexyl)carbonyl)-
- EN300-303645
- nateglinidum
- Nateglinide, Starlix
- NCGC00271534-02
- MLS006011429
- Nateglinide [USAN:USP:INN:BAN]
- Q-201449
- NATEGLINIDE [VANDF]
- Nateglinide, >=98% (HPLC), solid
- Q2254797
- CHEMBL2114389
- carboxamido)-3-phenylpropanoic acid
- AY-4166
- Tox21_111432_1
- KS-5143
- NS00073312
- s2489
- (R)-2-rel-((1r,4R)-4-Isopropylcyclohexanecarboxamido)-3-phenylpropanoicacid
- A1-02996
- D-Nateglinide
- AB00639979-09
- YM-026
- D01111
- DTXCID7020687
- OELFLUMRDSZNSF-BRWVUGGUSA-N
- (2R)-3-phenyl-2-{[(1r,4r)-4-(propan-2-yl)cyclohexyl]formamido}propanoic acid
- AKOS015960899
- {N}-[({TRANS}-4-ISOPROPYLCYCLOHEXYL)CARBONYL]-D-PHENYLALANINE
- NATEGLINIDE [MI]
- NCGC00271534-03
- DTXSID9040687
- NATEGLINIDE [USP-RS]
- trans-N-{[4-(1-methylethyl)cyclohexyl]carbonyl}-D-phenylalanine
- BCP28400
- NSC 758695
- NATEGLINIDE [WHO-DD]
- CHEBI:31897
- BDBM50344967
- Nateglinide, European Pharmacopoeia (EP) Reference Standard
- (trans-4-isopropylcyclohexane-1-carbonyl)-D-phenylalanine
- N-(Trans-4-Isopropylcyclohexylcarbonyl)-D-Phenyl Alanine
- trans-N-((4-(1-Methylethyl)cyclohexyl)carbonyl)-D-phenylalanine
- (R)-2-rel-((1r,4R)-4-Isopropylcyclohexanecarboxamido)-3-phenylpropanoic acid
- Nateglinide impurity C [EP]
- XTM4DQP5S5
- Nateglinide (JP17/USP/INN)
- D-Phenylalanine, N-[[4-(1-methylethyl)cyclohexyl]carbonyl]-, cis-
- AC-1690
- NATEGLINIDE [JAN]
- AB00639979_12
- HMS2235O08
- (2R)-2-[[oxo-(4-propan-2-ylcyclohexyl)methyl]amino]-3-phenylpropanoic acid
- NATEGLINIDE [MART.]
- (R)-2-((1r,4R)-4-isopropylcyclohexane
- NATEGLINIDE IMPURITY C [EP IMPURITY]
- NSC-758695
- n-(trans-4-isopropylcyclohexylcarbonyl)-d-phenylalanine
- NATEGLINIDE CIS-ISOMER [USP IMPURITY]
- BIDD:GT0257
- NATEGLINIDE [USAN]
- NS00000602
- Nateglinide cis-isomer [USP]
- Q27166439
- MLS000759500
- SCHEMBL9232138
- D-Phenylalanine, N-((4-(1-methylethyl)cyclohexyl)carbonyl)-, trans-
- NATEGLINIDE [EMA EPAR]
- MLS003915639
- DB00731
- SCHEMBL7880361
- NC00148
- N0912
- SDZ-DJN-608
- D-Phenylalanine, N-((cis-4-(1-methylethyl)cyclohexyl)carbonyl)-
- MLS001424043
- CAS-105816-04-4
- HMS3715F12
- HMS2089A10
- HMS3675G17
- NCGC00095121-01
- SDZ-DJN 608
- BRD-K44353683-001-08-3
- BRD-K44353683-001-07-5
- (R)-2-(cis-4-Isopropylcyclohexanecarboxamido)-3-phenylpropanoic acid
- STK647123
- NCGC00095121-12
- Nateglinide EP impurity C
- NCGC00095121-16
- BBL033469
- MDL： MFCD00875706
- Inchi： 1S/C19H27NO3/c1-13(2)15-8-10-16(11-9-15)18(21)20-17(19(22)23)12-14-6-4-3-5-7-14/h3-7,13,15-17H,8-12H2,1-2H3,(H,20,21)(H,22,23)/t15?,16?,17-/m1/s1
- InChI Key： OELFLUMRDSZNSF-OFLPRAFFSA-N
- SMILES： O=C(C1CCC(C(C)C)CC1)N[C@@H](C(=O)O)CC1C=CC=CC=1

Computed Properties

Exact Mass: 317.19900
Monoisotopic Mass: 317.199094
Isotope Atom Count: 0
Hydrogen Bond Donor Count: 2
Hydrogen Bond Acceptor Count: 3
Heavy Atom Count: 23
Rotatable Bond Count: 6
Complexity: 393
Covalently-Bonded Unit Count: 1
Defined Atom Stereocenter Count: 1
Undefined Atom Stereocenter Count : 0
Defined Bond Stereocenter Count: 0
Undefined Bond Stereocenter Count: 0
XLogP3: 3.2
Topological Polar Surface Area: 66.4

Experimental Properties

Color/Form: White crystalline powder
Density: 1.104
Melting Point: 137-141 oC
Boiling Point: 527.6 °C at 760 mmHg
Flash Point: 272.9 °C
Refractive Index: 1.536
Solubility: DMSO: >5mg/mL
PSA: 66.40000
LogP: 3.65180
Merck: 6428
Specific Rotation: -9.4° (c=1,in methanol)

Nateglinide Security Information

Signal Word：Warning
Hazard Statement： H315; H319; H335
Warning Statement： P261; P264; P271; P280; P302+P352; P304+P340; P305+P351+P338; P312; P321; P332+P313; P337+P313; P362; P403+P233; P405; P501
Hazardous Material transportation number：NONH for all modes of transport
WGK Germany：3
Hazard Category Code： R22: harmful if swallowed.
Safety Instruction： S24/25; S36
RTECS：SQ7318950
Hazardous Material Identification：
Toxicity：LD50 orally in rats: >2.0 g/kg (Hasegawa)
Storage Condition：Powder -20°C 3 years ? 4°C 2 years In solvent -80°C 6 months ? -20°C 1 month
Risk Phrases：R22

Nateglinide Customs Data

HS CODE：2924299090
Customs Data：

China Customs Code:
2924299090

Overview:

2924299090. Other cyclic amides(Including cyclic carbamates)(Including their derivatives as well as their salts). VAT:17.0%. Tax refund rate:13.0%. Regulatory conditions:nothing. MFN tariff:6.5%. general tariff:30.0%

Declaration elements:

Product Name, component content, use to, packing

Summary:

2924299090. other cyclic amides (including cyclic carbamates) and their derivatives; salts thereof. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0%

Nateglinide Pricemore >>

Related Categories	No.	Product Name	Cas No.	Purity	Specification	Price	update time
MedChemExpress	HY-B0422-10mM*1mLinDMSO	Nateglinide	105816-04-4	99.78%	10mM*1mLinDMSO	￥660	2022-05-18
MedChemExpress	HY-B0422-10mg	Nateglinide	105816-04-4	99.51%	10mg	￥500	2024-04-21
MedChemExpress	HY-B0422-50mg	Nateglinide	105816-04-4	99.51%	50mg	￥1540	2024-04-21
MedChemExpress	HY-B0422-100mg	Nateglinide	105816-04-4	99.51%	100mg	￥2800	2024-04-21
SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd.	N129568-1g	Nateglinide	105816-04-4	≥99%	1g	￥48.90	2023-09-01
SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd.	N129568-25g	Nateglinide	105816-04-4	≥99%	25g	￥498.90	2023-09-01
SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd.	N129568-250mg	Nateglinide	105816-04-4	≥99%	250mg	￥37.90	2023-09-01
SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd.	N129568-100g	Nateglinide	105816-04-4	≥99%	100g	￥1593.90	2023-09-01
SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd.	N129568-5g	Nateglinide	105816-04-4	≥99%	5g	￥155.90	2023-09-01
TI XI AI ( SHANG HAI ) HUA CHENG GONG YE FA ZHAN Co., Ltd.	N0912-5G	Nateglinide	105816-04-4	>98.0%(T)(HPLC)	5g	￥490.00	2024-04-18

Nateglinide Suppliers

Tiancheng Chemical (Jiangsu) Co., Ltd

Gold Member

Audited Supplier

(CAS:105816-04-4)Nateglinide, ≥ 98.0%

Order Number:LE12848;LE27065773

Stock Status:in Stock

Quantity:25KG,200KG,1000KG

Purity:99%

Pricing Information Last Updated:Friday, 20 June 2025 12:08

Price ($):discuss personally

Email:[email protected]

Zhengzhou Baoyu Pharmaceutical Co., Ltd.

Gold Member

Audited Supplier

(CAS:105816-04-4)Nateglinide

Order Number:LE013

Stock Status:in Stock

Quantity:5KG/1KG/25KG/100KG

Purity:99% HPLC

Pricing Information Last Updated:Thursday, 14 August 2025 14:44

Price ($):negotiated

Email:[email protected]

Nateglinide Spectrogram

LC-MS

LC-ESI-QFT

1H NMR

300 MHz

DMSO

13C NMR

Nateglinide Related Literature

1. Rapid screening for synthetic antidiabetic drug adulteration in herbal dietary supplements using direct analysis in real time mass spectrometry

Zhigui Zhou,Jialing Zhang,Wei Zhang,Yu Bai,Huwei Liu Analyst 2011 136 2613
2. Mechanochemical synthesis of drug–drug and drug–nutraceutical multicomponent solids of olanzapine

Kashyap Kumar Sarmah,Nilamoni Nath,Dharmaraj R. Rao,Ranjit Thakuria CrystEngComm 2020 22 1120
3. Discovery of anti-Ebola drugs: a computational drug repositioning case study

Prashant S. Kharkar,Ponnadurai Ramasami,Yee Siew Choong,Lydia Rhyman,Sona Warrier RSC Adv. 2016 6 26329
4. Insights into solute carriers: physiological functions and implications in disease and pharmacokinetics

Margarida Estudante,Gra?a Soveral,José G. Morais,Leslie Z. Benet Med. Chem. Commun. 2016 7 1462
5. SGLT inhibitors as antidiabetic agents: a comprehensive review

Rahul P. Kshirsagar,Abhishek A. Kulkarni,Rashmi S. Chouthe,Shahebaaz K. Pathan,Hemant D. Une,G. Bhanuprakash Reddy,Prakash V. Diwan,Siddique Akber Ansari,Jaiprakash N. Sangshetti RSC Adv. 2020 10 1733

Related Categories

Pharmaceutical and Biochemical Products Medical Target Class

Additional information on Nateglinide

Professional Introduction to Nateglinide (CAS No. 105816-04-4)

Nateglinide, a compound with the chemical name Nateglinide, is a medication primarily used in the management of type 2 diabetes mellitus. Its chemical structure and pharmacological properties have been extensively studied, making it a subject of significant interest in the field of pharmaceutical chemistry and medical research. The CAS number 105816-04-4 uniquely identifies this compound, ensuring precise classification and reference in scientific literature and industrial applications.

The development of Nateglinide has been driven by the need for more effective and rapid-acting treatments for type 2 diabetes. Unlike traditional oral antidiabetic agents, Nateglinide belongs to the glinide class, which works by stimulating insulin secretion from pancreatic beta cells in response to elevated blood glucose levels. This mechanism of action makes it particularly valuable for patients who require prompt reductions in postprandial glucose levels.

Recent advancements in the understanding of Nateglinide's pharmacokinetics have revealed its unique absorption and metabolic profile. Studies have demonstrated that Nateglinide is rapidly absorbed after oral administration, with peak plasma concentrations achieved within approximately 1 to 2 hours. This rapid onset of action is crucial for managing the sharp spikes in blood glucose that often follow meals in diabetic patients.

The compound's efficacy has been further supported by clinical trials that highlight its ability to significantly reduce postprandial glucose levels without causing hypoglycemia when used as monotherapy or in combination with other antidiabetic agents. The latest research indicates that Nateglinide may also offer additional benefits beyond glycemic control, such as improvements in insulin sensitivity and potential cardiovascular protective effects.

One of the key areas of investigation has been the molecular interactions between Nateglinide and its target enzymes, particularly ATP-sensitive potassium channels on pancreatic beta cells. Structural biology studies have provided insights into how Nateglinide modulates these channels, leading to increased insulin secretion. These findings have not only enhanced our understanding of the drug's mechanism but also opened new avenues for designing next-generation antidiabetic agents with improved efficacy and safety profiles.

The formulation of Nateglinide has also seen significant advancements to enhance patient compliance and therapeutic outcomes. Novel delivery systems, such as extended-release formulations, have been developed to provide more sustained glucose control over a longer period. These formulations aim to minimize the risk of hypoglycemia while maintaining effective glycemic management throughout the day.

Moreover, recent preclinical studies have explored the potential of Nateglinide in combination therapies targeting multiple pathways involved in diabetes pathophysiology. The compound's ability to synergize with other antidiabetic agents has raised hopes for more comprehensive treatment strategies that address both hyperglycemia and associated complications.

The regulatory landscape for Nateglinide has evolved alongside these scientific advancements, with regulatory agencies increasingly emphasizing evidence-based efficacy and safety data. Clinical trials now often incorporate innovative endpoints, such as patient-reported outcomes and long-term cardiovascular outcomes, to provide a more holistic assessment of the drug's benefits.

In conclusion, Nateglinide (CAS No. 105816-04-4) remains a cornerstone in the management of type 2 diabetes due to its rapid onset of action, efficacy in reducing postprandial glucose levels, and favorable safety profile. Ongoing research continues to uncover new insights into its pharmacological mechanisms and potential applications, reinforcing its importance as a therapeutic option in modern diabetes care.

105816-04-4 (Nateglinide) Related Products

Recommended suppliers